tailieunhanh - Báo cáo y học: "Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. | Available online http content 5 4 R181 Research article Open Access Serum cartilage oligomeric matrix protein COMP decreases in rheumatoid arthritis patients treated with infliximab or etanercept Meliha Crnkic1 Bengt Mânsson1 2 Lotta Larsson1 Pierre Geborek1 Dick Heinegârd2 and Tore Saxne1 2 Department of Rheumatology Lund University Hospital Lund Sweden 2Department of Cell and Molecular Biology Section for Connective Tissue Biology Lund University Lund Sweden Corresponding author Tore Saxne Received 9 Oct 2002 Revisions requested 20 Nov 2002 Revisions received 12 Mar 2003 Accepted 19 Mar 2003 Published 29 Apr 2003 Arthritis Res Ther 2003 5 R181-R185 DOI ar760 2003 Crnkic et al. licensee BioMed Central Ltd Print ISSN 1478-6354 Online ISSN 1478-6362 . This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract Changes in serum cartilage oligomeric matrix protein COMP were studied during a 6-month period from initiation of treatment of rheumatoid arthritis patients with either infliximab or etanercept to elucidate whether the favourable results of tissue protection reported in clinical trials are corroborated by changing levels of circulating COMP. Rheumatoid arthritis patients commencing treatment with infliximab N 32 or etanercept N 17 were monitored in accordance with a structured protocol. Only patients who were not receiving glucocorticoids or who were on a stable dose of oral prednisolone 10mg daily were included. Serum COMP was measured by a sandwich immunoassay based on two monoclonal antibodies against human COMP in samples obtained at treatment initiation and at 3 and 6 months. Serum COMP decreased at 3 months in both infliximab- and etanercept-treated patients P and respectively and remained low at 6 months. There was no significant correlation .